Printer Friendly

Generation of human monoclonal allergen-specific IgE and IgG antibodies from synthetic antibody libraries.

It is well established that the development of several immune-mediated diseases is linked to circulating concentrations of IgE, the antibody class responsible for allergic hypersensitivity (1). IgE antibodies bound to their high affinity receptor (Fc[epsilonRI) [3] on mast cells and basophils mediate receptor cross-linking by allergens and trigger degranulation and release of proinflammatory mediators responsible for immediate-type hypersensitivity reactions. Long-term exposure to higher concentrations of allergens or therapeutic intervention by specific immunotherapy (SIT) results in a T-helper cell type-1 shift in the immune response, leading to an increase in production of allergen-specific IgG antibodies, particularly of the IgG4 subclass. These IgG antibodies are thought to exert their function by blocking the IgE allergen interaction (2-4), by recruitment of Fcy receptors that inhibit FcsR mediated activation (5, 6), or by inhibition of IgE-facilitated allergen presentation to T cells (7).

The in vitro measurement of allergen-specific IgE and IgG in serum that are involved in induction and progression of disease has become a major diagnostic and prognostic goal to describe the immune status of an allergic patient and to assess the success of SIT. However, reliable determination of allergen-specific serum IgE or IgG4 antibodies is limited by the fact that human IgE antibody serum pools are not standardized and cannot be reproducibly prepared. The lack of availability of allergen specific IgG4 antibody pools of patient sera further complicates standardized methods. Standardization will likely become more important with the use of recombinant allergens for advanced diagnostics and intervention.

Our aim was to establish the generation of reproducible allergen-specific antibodies for the most relevant isotypes for allergy diagnostics and research. During the last decade combinatorial technologies have enabled the selection of a variety of monoclonal single-chain antibody fragments (scFv) against all types of antigens and epitopes (8-10). Although the selection of antibodies is often performed by using libraries built from lymphoid sources such as peripheral blood, bone marrow, or tonsils (11-13), this approach is of limited use for identifying allergy-relevant antibodies because of the evanescent number of IgE-producing cells and the highly individual reactivities of donors. In contrast, specificities against an almost unlimited panel of target molecules can be provided by synthetic library formats (14, 15), rendering their use attractive for the generation of antibodies against broad panels of allergens. To allow for their applicability in common laboratory methods, library-derived antibody fragments must be fused to Fc regions to overcome the monovalent format and the lack of constant region (Fc) effector domains. Such constructs were employed for recombinant production of scFv-Fc-fusions in mammalian cells (16-18) in Pichia pastoris (19), and to produce complete antibodies (20, 21).

We generated fully human IgE, IgG4, and IgG1 antibodies with defined specificity for 3 different allergens. From a human synthetic library, we selected scFv against the allergens and established their expression as human IgE, IgG4, and IgG1 antibodies. Expression of homodimeric or heterotetrameric recombinant proteins was performed in HEK-293 cells, and the antibodies were analyzed for allergen binding and formation of the allergen/IgE/IgE receptor complex. To our knowledge this is the first example of such a panel of IgE and IgG4 allergen-specific antibodies.

Material and Methods

MATERIALS

Target proteins for selection were phospholipase A2 from Apis mellifera (honey bee) venom, (Api m1) (Latoxan), milk [beta]-lactoglobulin (Bos d5; Sigma), and the recombinant allergen from apple (Mal d1; Biomay). The antigen for the murine scFv that was used in some constructs with human constant regions was hen egg lysozyme (Gal d4) (Sigma).

PANNING PROCEDURE

For generation of monoclonal antibody fragments we used the human synthetic antibody library Griffin-1 (10), which comprises scFv-formatted variable regions of human origin, providing a diversity of approximately 2 x [10.sup.9]. The allergens were employed for selection according to established protocols (10). Briefly, immunotubes coated with the particular allergen and blocked with 20 g/L milk powder phosphate buffered saline (MPBS; 50 mmol/L sodium phosphate, 100 mmol/L sodium chloride, 20 g/L milk powder, pH 7.4) were incubated with a total volume of 4 mL of 20 g/L MPBS containing 1012 to 1013 phages for 90 min under continuous rotation at room temperature. The immunotubes were then washed, 1 mL of 100 mmol/L triethylamine was added to elute the bound phages, and neutralization was performed by addition of 0.5 mL of 1 mol/L Tris-HCI, pH 7.4. After reinfection of Escherichia coli TG1 and overnight growth on agar plates, the phages were rescued by growth of scraped cells in liquid culture, infection with M13KO7 helper phage, and another period of overnight growth. Phages were then subjected to the next round of selection. Immunoreactivity of polyclonal or monoclonal phages was assessed in ELISA with anti-M13-horseradish peroxidase conjugate (Amersham Pharmacia Biotech) and 2,2azino-bis[beta]-ethyl-benzothiazoline-6-sulfonic acid) di-ammonium salt for detection.

AMPLIFICATION AND CLONING OF IMMUNOGLOBULIN CONSTANT REGIONS

The human immunoglobulin constant regions were synthesized from cDNA derived from human peripheral blood mononuclear cells employing standard reaction conditions.

The genes for human IgG1 and IgG4 heavy chain constant regions (IGHG1 and IGHG44) were amplified using PCR primers containing an AscI and a KpnI site ([[gamma]1: GAT CGG TAC CGA TCG GCG CGC CCA AAT CTT GTG ACA AAA CT CAC, [gamma]4: GAT CGG CGC GCC TTC CAC CAA GGG CCC ATC CGT CTT CCC CCT) and a SfiI site ([gamma]1: GAT CGG CCC AGC CGG CCT CAT TTA CCC GGA GAC AGG GAG AGG CTC TTC, [gamma]4: GAT CGG CCC AGC CGG CCT CAT TTA CCC AGA GAC AGG GA), the [gamma]1 [C.sub.H]2-3 and [gamma]4 [C.sub.H]2-3 domains using primers containing an AscI and a KpnI site ([gamma]1: GAT CTC TAG ATC ATT TAC CCG GAG ACA GGG AGA GGC TCT TC,-[gamma]1: GAT CGG CGC GCC CAG CAA CAC CAA GGT GGA CA) and a Xbal site ([gamma]1: GAT CGG CGC GCC AGC CTC CAC CAA GGG CCC AT, [gamma]1: GAT CTC TAG ATC ATT TAC CCA GAG ACA GGG A).

For amplification of the genes for the human IgE heavy chain constant regions (IGHE) we used primers containing an AscI site (GAT CGG CGC GCC CAT CCG TCT TCC CCT TGA), an SfiI site, a 4xhis-tag (GAT CGG CCC AGC CGG CCT CAT TTA CCG GGA TTT ACA GAC AC), and for the s [C.sub.H]2-4 domains we used primers containing an AscI site (GAT CGG CGC GCC CAC CGT GAA GAT CTT AC), an XbaI site, and a 4xhis-tag (GAT CTC TAG ATC AAT GGT GGT GAT GTT TAC CGG GAT TTA CAG ACA CCG).

The signal sequence of a gene for rat [kappa] light chain was synthesized by PCR primers containing a NheI site (GTA CGC TAG CAA GAT GGA ATC ACA GAC CCA GGT CCT CAT GTC CCT GCT GCT CTG GAT TTC) and a KpnI site (CAT GTC CCT GCT GCT CTG GAT TTC TGG TAC CTG TGG GGT GAG TCC TTA CAA CGC GTG TAC).

After introduction of the leader sequence into the mammalian expression vector pcDNA3.1-zeo (Invitrogen Life Technologies), we inserted the individual Ig domains, the Fc domains, and the entire heavy chains [gamma]1, [gamma]4, and s via the XbaI and the AscI sites. Transfer of the particular scFv into the scFv-[C.sub.H]2-3 or scFv-[C.sub.H]2-4 format was performed by introduction by PCR of a BszWI site at the N-terminus and an AscI site at the C-terminus. Subsequently, the DNA was ligated into the vectors containing the signal sequence and the particular constant regions.

For expression of the heterotetrameric IgG and IgE formats we used the mammalian expression vector pBudCE4.1 (Invitrogen Life Technologies). The human [kappa] light chain constant domain (IGKC) was amplified using one PCR primer containing an XbaI site and another primer containing an SgfI site (GAT CTC TAG ACT AAC ACT CTC CCC TGT TGA AGC and GAT CGC GAT CG C AC G AAC TGT GGC T GC ACC ATC T GT C). The 2 human signal sequences VH3-64 and VKI were synthesized by PCR using primers with an NotI and an internal SwaI or an SalI and an internal SbJI site for insertion of the variable regions (AGA ATG CGG CCG CTA TGG AAT TGG GGC TGA GCT GGG TTT TCC TTG TTG C TAT ATT TAAA TGT GTC CAG TGT and GAT CGT CGA CAT GGA CAT GAG GGT CCC CGC TCA GCT CCT GGG GCT CCT GCT ACT CTG CCT GCA GGG TGC CAG ATG T). After assembly of the leader sequences and the constant regions, the variable regions were then introduced via the SgfI and the SbJI sites, or the AscI and SwaI sites, respectively. Finally, the entire light chain sequence including the leader sequence was introduced via the XbaI and the SalI sites and the entire heavy chain including the leader sequence via the NotI site and the SfiI site into the expression vector pBudCE4.1.

AMPLIFICATION AND CLONING OF IGE HIGH-AFFINITY RECEPTOR SUBUNITS

Sequences coding for the subunits of the human IgE receptor (FCER1A, MS4A2, and FCER1G) were amplified from a cDNA library derived from human peripheral blood mononuclear cells. The a subunit was amplified with PCR primers containing an XbaI site (GAT CTC TAG AAT GGC TCC TGC CAT GGA ATC) and a BamHI site (GAT CGG ATC CTC AGT TGT TTT TGG GGT TTG GC), the [beta] subunit using primers containing a Not I site (GAT CGC GGC CGC TAT GGA CAC AGA AAG TAA TAG GAG) and an SfiI site (GAT CGG CCC AGC CGG CCT CAT AAA TCA ATG GGA GGA GAC ATT TC) and the [gamma] subunit using primers containing an NheI site (GAT CGC TAG CAT GAT TCC AGC AGT GGT CTT G) and a BamHI site (GAT CGG ATC CCT ACT GTG GTG GTT TCT CAT GC). Subsequently, the DNA was inserted into the expression vectors pcDNA3.1-neo or pBudCE4.1. The expression of the [gamma] chain is a prerequisite for surface expression of the [alpha] subunit and results in formation of functional receptor complexes of the [alpha][beta][gamma]2 type.

TRANSFECTION OF HEK-293 CELLS

HEK-293 cells (22) (ATCC number CRL-1573) were cultivated in DMEM supplemented with 100 mL/L fetal calf serum, 10 kIU/L penicillin, and 100 mg/L streptomycin. Tissue culture reagents were obtained from Invitrogen Life Technologies. HEK-293 cells were transfected with 2 [micro]g of the particular expression vector by use of polyethylene imine (Sigma). The secreted immunoglobulins were purified from the culture medium by affinity chromatography using protein A-agarose (Santa Cruz Biotechnologies.) or Ni-NTA-agarose (Qiagen) according to the manufacturers' recommendations.

ASSESSMENT OF IMMUNOREACTIVITY IN ELISA AND ALABLOT

For assessment of immunoreactivity in ELISA the particular proteins (diluted with 20 g/L MPBS) were applied to microtiter plates coated with particular antigens at 4 [degrees]C overnight and blocked with 50 g/L MPBS at room temperature for 1 h. Thereafter, ELISA was performed according to established protocols. For immunoblot procedures, the particular recombinant antibodies were diluted using DMEM supplemented with 100 mL/L heat-inactivated fetal calf serum and applied to the corresponding AlaBLOTs (F1, hen egg white; F2, bovine milk white; 11, whole bee venom; and F49, apple extract; DPC-Biermann) with native allergens, separated by SDS-PAGE, and immobilized onto nitrocellulose strips in the form of extracts or purified allergens. Visualization of bound IgE was then performed with monoclonal antihuman IgE conjugated to alkaline phosphatase (AP) and nitrotetrazolium blue chloride /5-bromo-4-chloro-3-indoyl phosphate according to recommendations of the manufacturer.

ASSESSMENT OF REACTIVITY WITH RECEPTORS

Interaction of the IgE antibodies with its receptor and with allergens was followed by flow cytometric analyses performed by use of a FRCS Calibur and CellQuest software (both Becton Dickinson). Labeling of antibodies and allergens with fluorescein isothiocyanate (FITC) (Sigma) was performed according to standard protocols. Fc[epsilonRI-expressing HEK-293 cells were resuspended in DMEM containing 100 mL/L fetal calf serum and seeded into 6-well microtiter plates at a density of 5 x [10.sup.5] cells/well. After overnight growth, FITC-labeled antibody constructs in a volume of 400 [micro]L were added and cells were incubated for 120 min at 4 [degrees]C and then washed 3 times with DPBS. Concentration of the antibody constructs was usually 2.5 nmol/L. Employing nonlabeled antibodies, cells were resuspended in 400 [micro]L DMEM containing 100 mL/L fetal calf serum and FITC-conjugated allergen. The resuspended cells were incubated for 120 min at 4 [degrees]C and then washed 3 times with DPBS. Controls consisted of cells resuspended in 500 [micro]L DPBS only.

[FIGURE 1 OMITTED]

OTHER METHODS

SDS-PAGE, immunoblotting, and ELISA as well as standard procedures in molecular biology were performed according to established protocols (23).

Results

SELECTION OF RECOMBINANT ANTIBODY FRAGMENTS

To generate monoclonal antibody fragments with specificity for different major allergens, we subjected the human synthetic antibody library Griffin-1 (10) to selection against the 3 purified allergens Api m1, Bos d5, and Mal d1 immobilized on polystyrene tubes. After iterative panning, significant enrichment in the 2nd and 3rd rounds of selection was assessed by polyclonal ELISA (data not shown). Subsequently, the individual phage clones exhibited signals 3-12 times background in the monoclonal ELISA. For each of the allergens individual reactive fragments were identified by sequence analysis (see Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol53/issue6).

EXPRESSION OF IGE AND IGG ANTIBODIES

For expression of selected scFv as different Ig isotypes in mammalian cells, we constructed a set of modular cassettes containing leader sequences, constant Ig regions, and restriction sites for the incorporation of scFv or separate variable regions. The [gamma]1, [gamma]4, and s heavy chain constant regions and a corresponding light chain constant region were amplified from a cDNA library derived from human peripheral blood mononuclear cells (data not shown). Fusion proteins were produced by use of modular cassettes containing signal sequence and restriction sites for cloning of variable and constant regions of both entire heterotetrameric antibodies as well as homodimeric scFv-C,12-4 or scFv-C,12-3 (Fig. 1). The entire panel of 6 expression formats was developed for the library-derived human antibody fragments Bos d5-1 and Api m1-9. Moreover, human scFv-based homodimeric formats were produced on the basis of antibody fragments selected against Api m1, Mal d1, and Bos d5 (Table 1). A murine scFv was employed for the primary establishment of the complete set of 6 different antibody types and formats against the allergen Gal d4 (one of each format for the human isotypes IgG1, IgG4, and IgE).

After purification from culture supernatants of transfected HEK-293 cells, SDS-PAGE demonstrated homogeneity of the antibody molecules, and immunoblotting verified the presence of the particular Ig chains (Fig. 2). Molecular masses were found to be 130 kDa and 150 kDa for the homodimeric scFv-based IgG- and IgE-analogous molecules, respectively, and 160 kDa and 190 kDa for the heterotetrameric IgG and IgE, respectively. The expected molecular masses in SDS-PAGE suggest that the majority of antibody secreted from the HEK-293 cells is properly folded and glycosylated, in particular the extensively glycosylated IgE.

[FIGURE 2 OMITTED]

ASSESSMENT OF IMMUNOREACTIVITY

Immunoreactivity of the resulting proteins was assessed by several approaches. All recombinant proteins detected their particular target allergen by ELISA (Fig. 3A). Moreover, specific immunoreactivity of the recombinant scFvIgE antibodies was demonstrated by detection of Api m1, Bos d5, and Gal d4 with commercial AlaBLOT immunoblot strips that contain a plethora of extracted antigens (Fig. 313) routinely employed in allergy diagnostics. The lack of reactivity by antibody Mal d1-7 in the AlaBLOT likely reflects recognition of a conformational epitope lost during immunoblotting. Most of these antibodies also bound to the appropriate allergen extracts immobilized to paper discs (data not shown).

[FIGURE 3 OMITTED]

Recombinant antibodies were added to serum from nonallergic individuals to produce human serum with defined reactivity. Dilutions of these supplemented sera in ELISA mimicked signals from individual sera from allergic individuals (Fig. 4A). The immunoreactivity of the scFv-based antibodies added to nonallergic serum remained stable for at least 1 week at room temperature (Fig. 4B).

ACTIVITY OF THE IGE ANTIBODIES IN CELLULAR ASSAY SYSTEMS

After stable transfection of HEK-293 cells with the a, [beta], and [gamma] subunits of the human Fc[epsilonRI, we identified transfectants expressing the functional receptor by use of FRCS using an [alpha] chain-specific antibody (Fig. 5A). Functionality of the receptor and binding of the recombinant antibodies were demonstrated by use of FITC-conjugated scFv-based IgE (data not shown). Specific binding of allergens via receptor-bound recombinant IgE could be shown by use of nonlabeled recombinant IgE antibodies and FITClabeled Gal d4 (Fig. 513) or FITC-labeled Api m1 (Fig. 5C). To mimic the decrease of allergen binding to receptorbound IgE in the presence of blocking allergen-specific IgG4 antibodies, the allergen was applied in the presence of IgE and IgG4 antibodies; subsequent FRCS analyses confirmed the inhibition of allergen binding to receptor-bound IgE (Fig. 513, D-F).

Discussion

In general, the presence of IgE vs IgG1 and IgG4 antibodies in allergy reflects the T-helper cell type 1/2 type immune milieu. Although the role of allergen-specific IgG responses after allergen exposure (24,25) has remained controversial (26, 27), the production of high-affinity IgG antibodies during SIT is of particular interest because such antibodies are thought to interfere with the IgE allergen interaction (2, 3) and could act as blocking antibodies (4). Their activity may rely either on molecular excess or on affinity maturation during vaccination (28). The ratio of serum concentrations of allergen-specific IgE and IgG4 antibodies is thought to reflect the immune status of an allergic patient and the success of SIT.

[FIGURE 4 OMITTED]

The unavailability of monoclonal IgG and IgE antibodies has thus far prohibited detailed analyses of their characteristics in pathophysiology as well as their molecular interplay. Approaches to generating human allergen-specific IgE-secreting hybridomas from immunized donors have not been successful (29). Furthermore the production of allergen-specific antibodies by conventional hybridoma technology is hampered by the low immunogenic potential of allergens, and the resulting murine antibodies are neither compatible with established human specific assay formats nor allow differentiation of different human isotypes.

[FIGURE 5 OMITTED]

Recently, the establishment of combinatorial approaches and the relatively easy generation of avian antibody phage libraries have enabled the production of allergen-specific chicken monoclonal scFv; however, this approach is also limited by time-consuming immunization procedures [beta]0). Chimerization of animal-derived antibodies by addition of desired human constant regions can open alternatives but is very time-consuming and is not specific for allergenic epitopes. Nonetheless, the recloning of murine hybridomas to chimeric IgE has been reported [beta]1). Indeed, we used a murine antibody fragment with specificity for Gal d4 to express recombinant human Fc antibodies. This approach supports the idea that available allergen-specific hybridomas may also provide suitable binding moieties for recombinant IgE and IgG antibody formats. The selection of IgE-derived antibody fragments from immune repertoires of human donors [beta]2, 33) is labor-intensive because of the evanescent number of IgE-producing cells, the highly individual reactivities of donors and the limited number of resulting clones makes this method unsuitable for minor allergens.

In contrast, as demonstrated in this study, synthetic libraries of human origin can quickly provide reactive antibody fragments against broad panels of available allergens by employing a high-diversity library of human scFv-formatted variable regions. The epitopes recognized by such antibody fragments may differ from the epitopes of allergens recognized by natural IgE antibodies. However, biochemical and structural characteristics may render particular epitopes favorable for both natural IgE antibodies and scFv obtained by selection processes. A possible example is the cross-reaction of the major allergen from the apple fruit Mal d1 with natural IgE specific for Bet v 1 and other homologs, which causes birch pollen related food allergies. For the recombinant antibody Mal d1-2 in our study, however, assessment using AlaBLOT revealed no evidence for such cross-reactivity with Bet v1. Supporting the potential of the phage-display technology, our selection process yielded a panel of reactive human antibody fragments for several common allergens. In honey bee venom, Api m1 represents the dominating major antigen in immunity as well as in allergy [beta]4). Bos d5 ([beta]-lactoglobulin) is a principle allergen in cow's milk. Compared to the conversion to entire heterotetrameric Igs (20, 21), a more convenient approach relies on the expression of homodimeric scFv-C,12-3 IgG fusions (16,19) that are easy to generate and purify and posess full binding and effector functions (19). For analogous IgE and IgG4 Fc fusion proteins of scFv, expression has not previously been produced.

Our transfection of HEK-293 cells yielded a set of scFv-based as well as entire heterotetrameric antibodies that are allergen-specific IgE, IgG1, and IgG4 antibodies. The immunoreactivity in direct ELISA of these recombinant IgE and IgG4 antibodies when added to nonallergic human serum and their reactivity in commercial immunoblots demonstrates their potential use in different types of immunological and allergy diagnostic methods.

Our analyses of IgE binding to the recombinant high-affinity receptor Fc[epsilonRI also demonstrate the compatibility of the recombinant proteins with cellular assay systems. Moreover, allergen binding to the Fc[epsilonRI could be blocked by IgG antibodies of the same allergen specificity. Because the recombinant IgE and IgG4 antibodies exhibit identical affinities due to their identical scFv moieties, the set of antibodies may mimic the circulating antibodies after affinity maturation of IgG antibodies that may occur after SIT.

Controversy exists regarding the affinities of allergen-specific IgE and IgG antibodies and the physiological relevance of their affinities [beta]5). The overall affinity of allergen-specific polyclonal IgG is thought to be significantly lower than that of allergen-specific polyclonal IgE (28). In contrast, antibody fragments isolated from immune libraries of allergic donors demonstrated comparably high affinities [beta]6), and analyses of IgG antibodies during SIT revealed no increase in IgG affinity [beta]7). These inconsistent findings may be partially explained by circulating IgE and IgG antibodies affinities that are highly variable without being discernible in immunoassays. The recombinant antibodies most likely exhibit high affinities attributable to the nature of the selection process and therefore correspond to the natural antibodies.

In summary, we used both combinatorial selection of synthetic antibody libraries and antibody technology to generate different formats of monoclonal allergen-specific IgE, IgG1, and IgG4 antibodies. The use of such reliable and precise reagents may help to establish novel reagents to aid in the standardization of allergen-specific diagnostic immunoassays and to minimize interassay variance. In addition, such defined antibodies are attractive tools for basic and applied research to evaluate the complex molecular interplay of allergens, different allergen-specific antibodies, and the different types of Fcs and Fcy receptors to better understand modulation of the allergic reaction. Finally, such approaches may have therapeutic applications including recruitment of negatively regulating receptors [beta]8) as well as passive or adjuvant immunotherapy (9).

Grant support/ funding: None declared. Financial disclosures: None declared.

Acknowledgements: We thank G. Winter, MRC Cambridge, for providing the synthetic scFv library Griffin-1.

Received February 12, 2007; accepted February 22, 2007. Previously published online at DOI: 10.1373/clinchem.2006.078360

References

(1.) Ishizaka K, Ishizaka T, Hombrook MM. Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity with gamma-E-globulin antibody. J Immunol 1966;97:840-53.

(2.) Cooke RA, Bernhard JH, Hebald S, Stull A. Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever). J Exp Med 1935;62:733-51.

(3.) Lichtenstein LM, Holtzmann NA, Burnett LS. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968;101: 317-24.

(4.) Jarolim E, Poulsen LK, Stadler BM, Mosbech H, Oesterballe 0, Kraft D, et al. A long-term follow-up study of hyposensitization with immunoblotting. J Allergy Clin Immunol 1990;85:996-1004.

(5.) Daeron M, Malbec 0, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995;95:577-85.

(6.) Malbec 0, Attal JP, Fridman WH, Daeron M. Negative regulation of mast cell proliferation by FcgammaRIIB. Mol Immunol 2002;38: 1295-9.

(7.) Van Neenven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163: 2944-52.

(8.) Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-7.

(9.) McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-4.

(10.) Griffiths AD, Williams SC, Hartley 0, Tomlinson IM, Waterhouse P, Crosby WL, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. Embo J 1994;13:324560.

(11.) Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 1991; 352:624-8.

(12.) Burton DR, Barbas CF III, Persson MA, Koenig S, Chanock RM, Lerner, RA. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A 1991;88:10134-7.

(13.) Barbas CF, III, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A 1991;88:7978-82.

(14.) Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222:58197.

(15.) Barbas CF III, Bain JD, Hoekstra DM, Lerner RA. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci U S A 1992;89:4457-61.

(16.) Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A 1999;96: 8161-6.

(17.) Terskikh AV, Le Doussal JM, Crameri R, Fisch I, Mach JP, Kajava AV. "Peptabody": a new type of high avidity binding protein. Proc Natl Acad Sci U S A 1997;94:1663-8.

(18.) Choi I, De Ines C, Kurschner T, Cochlovius B, Sorensen V, Olafsen T, et al. Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro. Eur J Immunol 2001;31:94-106.

(19.) Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, et al. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 2001;251:123-35.

(20.) Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, Boel E, et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 1999;17:276-81.

(21.) Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997;187:9-18.

(22.) Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.

(23.) Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, et al.. Current Protocols in Molecular Biology Greene Publishing Associates and Wiley-Interscience, New York, 1994.

(24.) Jarolim E, Rumpold H, Endler AT, Ebner H, Breitenbach M, Scheiner 0, et al. IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy 1989;44:385-95.

(25.) Kemeny DM, Urbanek R, Ewan P, McHugh S, Richards D, Patel S, et al. The subclass of IgG antibody in allergic disease II. The IgG subclass of antibodies produced following natural exposure to dust mite and grass pollen in atopic and non-atopic individuals. Clin Exp Allergy 1989;19:545-9.

(26.) Svenson M, Jacobi HH, Bodtger U, Poulsen LK, Rieneck K, Bendtzen K. Vaccination for birch pollen allergy: induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. Mol Immunol 2003;39:60 3-12.

(27.) Aalberse RC. Specific IgE and IgG responses in atopic versus nonatopic subjects. Am J Respir Crit Care Med 2000;162:124-7.

(28.) Hantusch B, Scholl I, Harwanegg C, Krieger S, Becker WM, Spitzauer S, et al. Affinity determinations of purified IgE and IgG antibodies against the major pollen allergens Phi p 5a and Bet v 1a: discrepancy between IgE and IgG binding strength. Immunol Lett 2005;97:81-9.

(29.) Zurcher AW, Lang AB, Aebischer I, Miescher S, Stadler BM. IgE-producing hybridomas established after B-cell culture in the CD40 system. Immunol Lett 1995;46:49-57.

(30.) Finlay WJ, deVore NC, Dobrovolskaia EN, Gam A, Goodyear CS, Slater JE. Exploiting the avian immunoglobulin system to simplify the generation of recombinant antibodies to allergenic proteins. Clin Exp Allergy 2005;35:1040-8.

(31.) Furtado PB, McElveen JE, Gough L, Armour KL, Clark MR, Sewell HF, et al. The production and characterisation of a chimaeric human IgE antibody, recognising the major mite allergen Der p 1, and its chimaeric human IgG1 anti-idiotype. Mol Pathol 2002;55: 315-24.

(32.) Steinberger P, Kraft D, Valenta R. Construction of a combinatorial IgE library from an allergic patient isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, phi p 5. J Biol Chem 1996;271:10967-72.

(33.) Laukkanen ML, Makinen-Kiljunen S, Isoherranen K, Haahtela T, Soderlund H, Takkinen K. Hevein-specific recombinant IgE antibodies from human single-chain antibody phage display libraries. J Immunol Methods 2003;278:271-81.

(34.) Muller U, Fricker M, Wymann D, Blaser K, Crameri R. Increased specificity of diagnostic tests with recombinant major bee venom allergen phospholipase A2. Clin Exp Allergy 1997;27:915-20.

(35.) Fromberg J. IgE as a marker in allergy and the role of IgE affinity. Allergy 2006;61:1234.

(36.) Jakobsen CG, Bodtger U, Kristensen P, Poulsen LK, Roggen EL. Isolation of high-affinity human IgE and IgG antibodies recognising Bet v 1 and Humicola lanuginosa lipase from combinatorial phage libraries. Mol Immunol 2004;41:941-53.

(37.) Jakobsen CG, Bodtger U, Poulsen LK, Roggen EL. Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance. Clin Exp Allergy 2005;35:193-8.

(38.) Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 2002;8: 518-21.

(39.) Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Valent P, et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 2002;32: 2156-62.

(40.) Kabat EA, Wu TT, Perry HM Gottesman KS, Foeller C. 1991 Sequences of Proteins of Immunological Interest, 5th ed, US Department of Health and Human Services, Bethesda, MD.

[3] Nonstandard abbreviations: Fc[epsilon]RI, high-affinity receptor for IgE; SIT, specific immunotherapy; scFv, single chain fragment variable; FACS, fluorescence activated cell sorting; [C.sub.H], immunoglobulin heavy chain constant domain; MPBS, milk powder phosphate buffered saline; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; Ap, alkaline phosphatase; and FITC, fluoresceine isothiocyanate.

[4] Human genes: IGHG1 human IgG1 heavy chain constant region; IGHG4 human IgG4 heavy chain constant region; and IGHE, human IgE heavy chain constant region; FCERIA, Fc fragment of IgE, high affinity I, receptor for; alpha polypepfide; FCER1G, Fc fragment of IgE, high affinity I, receptor for; gamma polypepfide; MS4A2, membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for beta polypeptide).

INGKE BRAREN, [1] SIMON BLANK, [1] HENNING SEISMANN, [1] SUSANNE DECKERS, [1] MARKUS OLLERT, [2] THOMAS GRUNWALD, [1] and EDZARD SPILLNER [1]*

[1] Institute of Biochemistry and Food Sciences, Division of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany.

[2] Department of Dermatology and Allergy, Biederstein Technical University, Mimchen, Germany.

* Address correspondence to this author at: Institut fur Biochernie and Molekularbiologie, Universit5t Hamburg, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany. Fax ++49-40-428387255; e-mail spillner@chemie.unihamburg.de.
Table 1. Antibody formats constructed and produced from
antibody fragments.

Allergen Antibody IgG1 IgG4
 fragment

Gal d4 Gal d4 + +
 (Lysozyme)
Bos d5 Bos d5-1 + +
 ([beta]- Bos d5-4
 Lactoglobulin) Bos d5-6
Api m1 Bos d5-10
 (Phospholipase A2) Api m1-2
 Api m1-9 + +
Mal d1 Mal d1-2
 (Apple) Mal d1-7

Allergen Antibody IgE scFv-I9G1
 fragment [C.sub.H2-3]

Gal d4 Gal d4 + +
 (Lysozyme)
Bos d5 Bos d5-1 + +
 ([beta]- Bos d5-4 +
 Lactoglobulin) Bos d5-6 +
Api m1 Bos d5-10 +
 (Phospholipase A2) Api m1-2 +
 Api m1-9 + +
Mal d1 Mal d1-2 +
 (Apple) Mal d1-7 +

Allergen Antibody scFv-IgG4 scFv-IgE
 fragment [C.sub.H2-3] [C.sub.H2-3]

Gal d4 Gal d4 + +
 (Lysozyme)
Bos d5 Bos d5-1 + +
 ([beta]- Bos d5-4 + +
 Lactoglobulin) Bos d5-6 + +
Api m1 Bos d5-10 + +
 (Phospholipase A2) Api m1-2 + +
 Api m1-9 + +
Mal d1 Mal d1-2 + +
 (Apple) Mal d1-7 + +
COPYRIGHT 2007 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Molecular Diagnostics and Genetics
Author:Braren, Ingke; Blank, Simon; Seismann, Henning; Deckers, Susanne; Ollert, Markus; Grunwald, Thomas;
Publication:Clinical Chemistry
Date:May 1, 2007
Words:5463
Previous Article:SPP I promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum.
Next Article:Homocysteine, 5, 10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24 968 initially...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters